Top Long Term Stocks To Buy Right Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of staffing service specialist Kforce (NASDAQ: KFRC  ) plunged 16% today after its quarterly results missed Wall Street expectations.

So what: The stock has slumped in recent weeks on concerns over slowing growth, and today's second-quarter results -- adjusted EPS slumped 25%, while revenue slipped 1% -- only reinforce those worries. Additionally, ADP's private survey results this morning indicated that the labor market is cooling, giving investors even more reason to doubt a near-term turnaround.

Now what: Management now sees second-quarter EPS of $0.19-$0.21 on revenue of $277 million-$281 million. "We are making progress toward our goal of accelerating revenue growth in the back half of the year, but there remains much work to do," CFO David Kelly said. "We remain confident in our strategy and long term prospects and expect to capitalize on the operating platform we have built to grow revenue and generate operating leverage." More important, with the stock now off about 25% from its 52-week highs, and trading at a forward P/E of 10, buying into that optimism might be worth looking into. ���

Best Railroad Stocks To Own Right Now: Altria Group(MO)

Altria Group, Inc., through its subsidiaries, engages in the manufacture and sale of cigarettes, smokeless products, and wine in the United States and internationally. It offers cigarettes under the Marlboro, Virginia Slims, Parliament, Benson & Hedges, Basic, and L&M brands; smokeless tobacco products under the Copenhagen, Skoal, Red Seal, Husky brands, and Marlboro snus brands; and machine-made large cigars and pipe tobacco. The company also produces and sells blended table wines under the Chateau Ste Michelle and Columbia Crest names; and distributes Antinori and Villa Maria Estate wines and Champagne Nicolas Feuillatte in the United States. In addition, it maintains a portfolio of leveraged and direct finance leases in rail and surface transport, aircraft, electric power, real estate, and manufacturing. The company sells its tobacco products to wholesalers, including distributors; large retail organizations, such as chain stores; and the armed services. Altria Group, Inc. markets its wine products to restaurants, wholesale clubs, supermarkets, wine shops, and mass merchandisers. The company was founded in 1919 and is headquartered in Richmond, Virginia.

Advisors' Opinion:

• [By Rich Smith]

  Philip Morris stock is at the bottom of the pack
  When you stack up Philip Morris stock against its rivals, it quickly becomes apparent that investors have been overpaying for an inferior company. Valued on its earnings, a share of Philip Morris stock will cost you 18.1 times earnings today, while a share of former parent Altria (NYSE: MO  ) costs only 17.2 times earnings, and a pack of Lorillard (NYSE: LO  ) shares sells for a P/E of just 14.1 -- 22% cheaper than Philip Morris.

• [By abirk] a's Philip Morris USA holds a 50% share of the U.S. tobacco market with a 60% share in the premium brand segment. Altria, whose brands include top-selling Marlboro cigarettes, Skoal smokeless tobacco and Black & Mild cigars, also reaffirmed its 2013 full-year adjusted earnings forecast of between $2.35 and $2.41 per share.

  The company holds a voting stake in brewer SABMiller, owns wine businesses and has a financial services division. The company's diversification into smokeless tobacco is crucial to promoting its growth due to the declining market for smokers in the U.S.

  Philip Morris USA is Altria's domestic cigarette manufacturing company. Philip Morris remains the largest tobacco company in the United States by both revenue and volume. It owns UST, the world's largest moist smokeless tobacco manufacturer by sales. UST provides Altria with the leading smokeless tobacco brands, Skoal and Copenhagen.

  It has a strong dividend growth history. With a current dividend yield of 5%, its dividend payout ratio based on consensus estimates for earnings this year is 73.3%. Next year, it is expected to earn $2.57 per share. If the payout ratio remains the same, annual dividends would come to $1.88 per share, which means a dividend increase of about 6.8%. As of March 2013, cash increased to $3.8 billion. The company is in a strong financial position based on this, and has additional cash to further strengthen this position.

  Reynolds American (RAI)

  Reynolds American and Lorillard hold 29% and 10% of the market share, respectively. Reynolds American offers cigarettes under the brand names of Camel, Pallmall, Winston, Kool, etc. It produces more savings brands, making it likely to benefit from consumers switching from premium to value brands. With a current dividend yield of 5.3%, this North Carolina based company has the highest payout ratio of 78.5%. The company is expected to grow its earnings to $3.40 per share next year. As of March 2013, it

• [By Lawrence Meyers]

  Everyone�� heard of the big tobacco companies like Altria (MO), but did you ever wonder who actually sells the tobacco leaves to the big tobacco manufacturers? I love the distribution business and that�� why I love Universal Corporation (UVV).

Top Long Term Stocks To Buy Right Now: Luminex Corporation(LMNX)

Luminex Corporation engages in the development, manufacture, and sale of proprietary biological testing technologies and products for the life sciences and diagnostic industries. It offers xMAP technology, an open architecture and multiplexing technology that allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres. The company?s xMAP technology is used in various segments of the life sciences industry, such as the fields of drug discovery and development, clinical diagnostics, genetic analysis, bio-defense, food safety, and biomedical research. It operates in two segments, Technology and Strategic Partnerships; and Assays and Related Products. The Technology and Strategic Partnerships segment provides Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGP IX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. This segment also offers consumables comprising dyed polystyrene microspheres and sheath fluids. The Assays and Related Products segment develops and sells assays on xMAP technology for use on its installed base of systems. This segment?s products are focused on the human genetics, personalized medicine, and infectious disease segments of the genetic testing market. This segment provides various assay products, which consist of a combination of chemical and biological reagents, and company?s proprietary bead technology used to perform diagnostic and research assays on samples. It serves pharmaceutical companies, clinical laboratories, research institutions, and medical institutions in the United States, Europe, Asia, Canada, and Australia. The company was founded in 1995 and is headquartered in Austin, Texas.

Advisors' Opinion:

• [By Seth Jayson]

  Basic guidelines
  In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Luminex (Nasdaq: LMNX  ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Luminex doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 9.1%, and inventory increased 32.2%. Comparing the latest quarter to the prior-year quarter, the story looks potentially problematic. Revenue grew 9.2%, and inventory grew 32.2%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 4.2%, and inventory grew 8.0%.

• [By Markus Aarnio]

  Illumina's competitors include Affymetrix (AFFX), Life Technologies Corporation (LIFE) and Luminex Corporation (LMNX). Here is a table comparing these companies.

• [By Roberto Pedone]

  A health care stock that insiders are jumping into here is Luminex (LMNX), which develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Insiders are buying this stock into notable strength, since shares are up 23.2% so far in 2013.

  Luminex has a market cap of $859 million and an enterprise value of $784 million. This stock trades at a premium valuation, with a price-to-sales of 119.83 and a price-to-book of 33.63. Its estimated growth rate for this year is 36.7%, and for next year it's pegged at 51.2%. This is a cash-rich company, since the total cash position on its balance sheet is $42.97 million and its total debt is just $1.67 million.

  A director just bought 27,000 shares, or about $540,000 worth of stock, at $20.01 per share.

  From a technical perspective, LMNX is currently trending above its 200-day and just below is 50-day moving average, which is neutral trendwise. This stock recently gapped down sharply from $23.50 to $19.75 a share with heavy downside volume flows. Following that move, shares of LMNX have started to rebound off $19.75 and the stock is starting to push within range of triggering a near-term breakout trade.

  If you're bullish on LMNX, then look for long-biased trades as long as this stock is trending some key near-term support at $19.75, and then once it breaks out above its 50-day at $21.14 a share and above its gap down day high of $21.83 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 206,755 shares. If that breakout hits soon, then LMNX will set up to re-test or possibly take out its 52-week high at $24.10. Any high-volume move above that level will then give LMNX a chance to tag $25 to $26.

Top Long Term Stocks To Buy Right Now: Granite Construction Inc (GVA)

Granite Construction Incorporated (Granite), incorporated on January 24, 1990, is a diversified heavy civil contractors and construction materials producers in the United States. The Company operates in four segments: Construction, Large Project Construction, Construction Materials and Real Estate. The Company operates nationwide, serving both public and private sector clients. Within the public sector, it primarily concentrates on heavy-civil infrastructure projects, including the construction of roads, highways, mass transit facilities, airport infrastructure, bridges, dams and other infrastructure related projects. Within the private sector, it performs site preparation and infrastructure services for residential development, commercial and industrial buildings, and other facilities. The Company owns and leases substantial aggregate reserves and own a number of construction materials processing plants. It also has contractor-owned heavy construction equipment fleets in the United States. In December 2012, it purchased 100% interest of Kenny Construction Company (Kenny).

Construction

Revenue from its Construction segment was approximately 47% of its total revenue during the year ended December 31, 2012. Revenue from its Construction segment is derived from both public and private sector clients. The Construction segment performs various heavy civil construction projects with a large portion of the work focused on new construction and improvement of streets, roads, highways, bridges, site work and other infrastructure projects. These are typically bid-build projects completed within two years.

Large Project Construction

Revenue from its Large Project Construction segment was 41.4% of its total revenue in 2012. The Large Project Construction segment focuses on large, complex infrastructure projects, which typically have a longer duration than its Construction segment work. These projects include major highways, mass transit facilities, bridges, tunn! els, waterway locks and dams, pipelines, canals and airport infrastructure. This segment primarily includes bid-build, design-build and construction management/general contractor contracts. It participates in joint ventures with other construction companies mainly on projects in its Large Project Construction segment. Joint ventures are typically used for large, technically complex projects, including design/build projects, where it is desirable to share risk and resources. Joint venture partners typically provide independently prepared estimates, shared financing and equipment and often bring local knowledge and expertise.

The Company also utilizes the design/build and construction management/general contract methods of project delivery. Under the construction management/general contract method of delivery, it contracts with owners to manage the design phase of the contract with the understanding that it will negotiate a contract on the construction phase when the design nears completion. Revenue from design/build and construction management/general contract projects represented 74.5% of Large Project Construction revenue in 2012.

Construction Materials

Revenue from its Construction Materials segment was 11.1% of its total revenue in 2012. The Construction Materials segment mines and processes aggregates and operates plants that produce construction materials for internal use and for sale to third parties. It has aggregate reserves that it has acquired by ownership in fee or through long-term leases. Aggregate products used in its construction projects represented approximately 42.7% of its tons sold during 2012.

Real Estate

Granite Land Company (GLC) is an investor in a diversified portfolio of land assets and provides real estate services for other Granite operations. GLC�� investment portfolio consists of residential, as well as retail and office site development projects for sale to home and commercial property developers. The range! of its i! nvolvement in an individual project may vary from passive investment to management of land use rights, development, construction, leasing and eventual sale of the project. Generally, GLC has teamed with partners who have local knowledge and expertise in the development of each property. GLC�� investments are located in Washington, California and Texas. Revenue from GLC was 0.2% of its total revenue in 2012.

Advisors' Opinion:

• [By Louis Navellier]

  If we look at the sector using Portfolio Grader, we see that many of the big names in the group like Flour (FLR), Granite Construction (GVA) and KBR incorporated (KBR) are rated ��ell.��The anticipated spending for both government and private industry simply hasn�� materialized, and the companies are not seeing revenue or profit growth.

• [By Wallace Witkowski]

  Some of the companies most dependent on government for revenue are Harris Corp. (HRS) �with 80% of revenue government-derived; Granite Construction Inc. (GVA) �with 58%; Flir Systems Inc. (FLIR) �with 54%; and Waste Management Inc. (WM) � and Republic Services Inc. (RSG) �both with 50%, according to Goldman Sachs.

Top Long Term Stocks To Buy Right Now: Bayer AG (BAYRY.PK)

Bayer AG is a management holding company. The Company�� business operations are organized into three subgroups: HealthCare, CropScience and MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. Bayer HealthCare is involved in the research, development and manufacture of health products for people and animals. Bayer CropScience is engaged in the crop protection and non-agricultural pest control. Bayer MaterialScience supplies polymers, and develops solution for a range of applications. In November 2009, Bayer MaterialScience acquired the polymer coatings business from Lombard Medical Technologies PLC. On November 2, 2009, it acquired Athenix Corporation. On October 1, 2009, it acquired two dermatology product lines from SkinMedica, Inc., Carlsbad, California, United States. On June 25, 2009, it acquired the remaining 10% interest in Bayer Polymers (Shanghai) Co. Ltd., China. In May 2009, it acquired the remaining 49% interest in Berlimed, s.a., Spain, from Juste s.a. Quimica Farmac茅utica (Juste), and in return sold its 51% interest of Justesa Imagen, s.a., Spain, to Juste. In May 2009, it also sold the Thermoplastics Testing Center, Krefeld, Germany, to Underwriters Laboratories Inc. In March 2010, the Company announced that its Bayer MaterialScience LLC has acquired Artificial Muscle, Inc, a company active in electroactive polymers for the consumer electronics industry.

Bayer HealthCare

The Company researches, develops, manufactures pharmaceutical and medical products. Bayer HealthCare operates in four operating divisions: Animal Health, which is engaged in manufacture of veterinary medicines and grooming products; Bayer Schering Pharma, which is engaged in manufacture of prescription medicines; Consumer Care, which is engaged in the manufacture of over-the-counter medicines and dietary supplements, and Medical Care, which is engaged in manufacture of blood glucose monitoring devices and contrast agent injecti! on systems. Its products for farm animals include Baytril. Its products for companion animals include Advantage/Advantix and Baytril. Its drug discovery in the pharmaceuticals segment focuses on the areas of cardiology, oncology,

women�� healthcare and diagnostic imaging.

Bayer CropScience

CropScience maintains a global network of research and development facilities. In the Crop Protection segment it identifies and develops safe and economically sustainable insecticides, fungicides and herbicides and carries its research projects in areas, such as plant health or stress tolerance. As of December 31, 2009, its active ingredient pipeline of Crop Protection contained 20 development projects, of which 10 was at an advanced stage and 10 at an early stage of development, and an additional 45 projects was undergoing early-stage research. Its operations are structured into six business operations units: four regional Crop Protection units plus the Environmental Science and BioScience units. Its insecticides include Confidor/ Admire, Calypso, Decis, Temik and Oberon. Its fungicides include Antracol, Fandango, Flint/Stratego/Sphere/Twist, Folicur and Previcur Energy. Its herbicides include Atlantis, Basta, Betanal, Fenikan, Hoestar, Husar, MaisTer, Puma. Its seed treatment products include Bariton, Gaucho, Lamarador, Poncho and Raxil.

Bayer MaterialScience

The Company supplies materials, such as polycarbonates and polyurethanes and system solutions for a range of everyday uses. It operates in three business units: Polyurethanes, Polycarbonates, and Coatings, Adhesives and Specialties. Its Coatings, Adhesives, Specialties producst include Desmodur, Bayhydur, Dispercoll and Artwalk. Its Polycarbonates include Makrolon, Makrofol / Bayfol, Fantasia and Bayblend. Its Polyurethanes include Multitec, Baydur, Bayflex, Baypreg and Vulkollan. Its Thermoplastic Polyurethanes include Desmopan / Texin.

Advisors' Opinion:

• [By Henry Kawabe]

  In June, Seattle Genetics announced it entered into a collaboration with Bayer HealthCare (BAYRY.PK) for access to its Seattle Genetics' auristatin-based ADC technology to create cancer drugs that home in on tumors and then deliver a toxic dose to their cells. The collaboration will generate upfront and option exercise fees of up to $20 million. Seattle Genetics is also eligible to receive up to approximately $500 million in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration.

• [By Bioassociate Consulting]

  KYTH holds a collaboration agreement with Bayer's (BAYRY.PK) dermatology division to develop and commercialize ATX-101 outside the United States and Canada, and is eligible to receive up to $297m in additional regulatory and commercialization milestones, as well as escalating sales royalties in mid to high-teens. Bayer completed two pivotal Phase III trials of ATX-101 in Europe for the reduction of submental fat. During June 2012, Kythera released results from these studies, in which ATX-101 achieved a statistically significant reduction in submental fat based on clinician, patient and objective ratings.